Strategic partnerships Opportunity to re-engage with Taueret Laboratories via partnership discussions around predictive testing and endometriosis in collaboration with Predictive Technology Group or InceptionDx assets, leveraging their historical focus on ARTguide and gene activation research.

Lifecycle of assets Given the 2018 asset sale to Predictive Technology Group and subsequent positioning with InceptionDx, there may be continued need for contract research, lab services, or asset redevelopment support to maximize value from previously developed DNA, ancestry, and related assets.

Clinical research needs Taueret’s involvement in gene activation studies and endometriosis testing indicates potential demand for specialized assays, genomic analysis, and biobank or lab instrumentation services to support niche clinical research programs.

Emerging collaboration potential Past partnerships with ASEA on molecular activation suggests an openness to external collaborations in translational biology; a BD approach could target consumer biotech synergies or tech transfer opportunities with wellness-focused partners.

Sustainability and scale Smaller biotech with limited revenue presents an opportunity for scalable, cost-efficient CRO/CMO services and technology platforms that help accelerate prototype testing, regulatory readiness, and portfolio development while managing financial risk.